Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Baudax Bio, Inc.BXRX · Entity 109081 | Director | April 07, 2021 | April 08, 2021 |
| INSMED IncINSM · Entity 3174 | Director | May 13, 2024 | May 15, 2024 |
| Societal CDMO, Inc.REPH · Entity 92137 | Director | December 05, 2019 | December 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Baudax Bio, Inc.
Report date April 07, 2021 · Filed April 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,785 |
Reported balance
After 2021-04-07 transaction · row 1
1 source rowRow 1 · 2021-04-07 · Grant · Acquired 56,452 · Balance 117,785 F1: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2031-04-07 | Direct | 83,333 |
Reported balance
After 2021-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-07 · Grant · Acquired 83,333 · Balance 83,333 F2: The stock option will vest on April 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date.
F2: The stock option will vest on April 7, 2022.
INSMED Inc
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,495 |
Reported balance
After 2024-05-13 transaction · row 1
1 source rowRow 1 · 2024-05-13 · Grant · Acquired 13,162 · Balance 69,495 F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2: Each RSU was granted on May 13, 2024 for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date.
F2: Each RSU was granted on May 13, 2024 for no consideration.
Societal CDMO, Inc.
Report date December 05, 2019 · Filed December 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,196 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 15,284 · Balance 44,196 F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGILE THERAPEUTICS INC
Report date August 26, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-26 · Disposition to issuer · Disposed 28,125 · Balance 19,624 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 28,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $42,750, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Row 2 · 2024-08-26 · Disposition to issuer · Disposed 19,624 · Balance 0 F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 19,624 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $29,828, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 28,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $42,750, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 19,624 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $29,828, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2024 Filed Aug 26, 2024 17:33 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 19,624 | $1.52 | $29,828.48 |
DisclosureSEC source: 0001104659-24-092937 · tm2422466-3_4seq1.xml · nonDerivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Upon the consummation of the Merger, pursuant to the Merger Agreement, 19,624 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $29,828, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 17:33 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 28,125 | $1.52 | $42,750.00 |
DisclosureSEC source: 0001104659-24-092937 · tm2422466-3_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,624 F1 · shares: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 28,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $42,750, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:14 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-023555 · wk-form4_1715804068.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,495 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. The RSUs have a one year cliff vesting period, provided that the director (a) remains a member of the Board of Directors of the issuer on such vesting date, and (b) attends at least 75% of the meetings of the Board of Directors which take place between the grant date and the first anniversary of the grant date. F2 · price: Each RSU was granted on May 13, 2024 for no consideration. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:37 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001104659-23-077176 · tm2320328-3_4seq1.xml · derivative · entry 3 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-27 F4 · derivative.exercise_date: This option was granted on June 28, 2023. 25% of the shares subject to the stock option vest on June 28, 2024, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on June 28, 2027. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:37 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 8,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077176 · tm2320328-3_4seq1.xml · nonDerivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,749 F3 · shares: These shares represent RSUs that were granted on June 28, 2023, which will vest and be settled in common stock on June 28, 2024. F2 · balance_after: On April 10, 2023, the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:37 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077176 · tm2320328-3_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,786 F1 · shares: These shares represent restricted stock units ("RSUs") which were granted on June 28, 2023. The RSUs will vest in four equal installments over four years upon the anniversary of the grant, such that the RSUs will be fully vested on June 28, 2027. F2 · balance_after: On April 10, 2023, the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:19 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 13,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018193 · wf-form4_168418195780663.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,333 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2023, for no consideration. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 16:34 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001104659-22-118636 · tm2230300-3_4seq1.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-11-08 F1 · derivative.exercise_date: This option was granted on November 9, 2022. 25% of the shares subject to the stock option vest on November 9, 2023, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on November 9, 2026. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 08:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 50,000 | $0.45 | $22,500.00 |
DisclosureSEC source: 0001104659-22-095384 · tm2224680-1_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,343 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4467 to $0.4498, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:17 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 14,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019185 · form4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,141 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 11, 2022, for no consideration. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-22-006130 · tm224102-3_4seq1.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022. 25% of the shares subject to the stock option vest on January 19, 2023, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 19, 2026. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 08:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseWarrants (right to buy) · Derivative | 29,412 | Not disclosed Strike: $0.85 | Not disclosed |
DisclosureSEC source: 0001104659-21-126012 · tm2129958-1_4seq1.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,412 Underlying: Common Stock · 29,412 shares Expires 2026-10-13 F1 · price: The reporting person purchased the reported securities at a combined public offering price of $0.85 per one share of common stock together with one-half of a warrant to purchase one share of common stock. Read SEC document |
| October 13, 2021 Filed Oct 14, 2021 08:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 58,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126012 · tm2129958-1_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,734 F1 · price: The reporting person purchased the reported securities at a combined public offering price of $0.85 per one share of common stock together with one-half of a warrant to purchase one share of common stock. Read SEC document |
| July 29, 2021 Filed Jul 29, 2021 19:52 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 26,200 | $1.26 | $33,095.84 |
DisclosureSEC source: 0001104659-21-097783 · tm2123597d2_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,910 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.26 to $1.3299, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 18, 2021 Filed May 19, 2021 08:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 20,000 | $1.61 | $32,200.00 |
DisclosureSEC source: 0001104659-21-069099 · tm2116049-2_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,710 Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:21 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 7,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017413 · form4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,496 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2021, for no consideration. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 19:03 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantStock Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001192482-21-000326 · edgar.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires 2031-04-07 F2 · derivative.exercise_date: The stock option will vest on April 7, 2022. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 19:03 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 56,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000326 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,785 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| March 23, 2021 Filed Mar 23, 2021 17:24 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 12,500 | $2.00 | $25,030.00 |
DisclosureSEC source: 0001104659-21-040396 · tm2110667-1_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,710 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.9950 to $2.0050, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 18:37 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 692,641 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001104659-21-008906 · tm214338d1_4seq1.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,641 Underlying: Common Stock · 692,641 shares Expires 2031-01-26 F1 · derivative.exercise_date: This option was granted on January 27, 2021. 25% of the shares subject to the stock option vest on January 27, 2022, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 27, 2025. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:09 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 20,000 | $39.57 | $791,400.00 |
DisclosureSEC source: 0001104659-20-133640 · tm2036583-3_4seq1.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,938 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 20,000 shares sold at prices ranging from $39.01 to $40.14 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 16:08 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | PurchaseCommon Stock | 5,000 | $1.06 | $5,299.50 |
DisclosureSEC source: 0001192482-20-000795 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,333 Read SEC document |
| August 20, 2020 Filed Aug 20, 2020 16:15 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 94,599 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001104659-20-097236 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,599 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 9, 2010 and is currently fully vested and exercisable. Read SEC document |
| August 20, 2020 Filed Aug 20, 2020 16:15 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 94,599 | $1.76 | $166,494.24 |
DisclosureSEC source: 0001104659-20-097236 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001104659-20-076109 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,599 Underlying: Common Stock · 50,000 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 9, 2010 and is currently fully vested and exercisable. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 50,000 | $1.76 | $88,000.00 |
DisclosureSEC source: 0001104659-20-076109 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:58 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 8,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-061853 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,938 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of the vesting date. F2 · price: Each Restricted Stock Unit was granted on May 12, 2020 for no consideration. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:18 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantStock Option (right to buy) · Derivative | 34,574 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000332 · edgar.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,574 Underlying: Common Stock · 34,574 shares Expires 2030-05-06 F2 · derivative.exercise_date: The stock option will vest on May 6, 2021. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:18 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 22,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000332 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,333 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 6, 2021. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 15:51 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | PurchaseCommon Stock | 5,000 | $2.34 | $11,700.00 |
DisclosureSEC source: 0001192482-20-000259 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,382 F1 · price: Represents the weighted average sale price of $2.3442. The range of prices for the sale of these shares was $2.3300 - $2.3500 rounded to the nearest ten-thousandths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 21:27 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,541 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001104659-20-026463 · a4.xml · derivative · entry 3 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,541 shares Expires 2020-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 21:27 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 10,000 | $2.71 | $27,100.00 |
DisclosureSEC source: 0001104659-20-026463 · a4.xml · nonDerivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,611 Read SEC document |
| February 27, 2020 Filed Feb 27, 2020 21:27 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 16,541 | $0.71 | $11,744.11 |
DisclosureSEC source: 0001104659-20-026463 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 19:59 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 833,333 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001104659-20-006858 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,333 Underlying: Common Stock · 833,333 shares Expires 2030-01-21 F2 · derivative.exercise_date: This option was granted on January 22, 2020. 25% of the shares subject to the stock option vest on January 22, 2021, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 22, 2024. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 19:59 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 26,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-006858 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,070 F1 · shares: These shares represent restricted stock units which were granted on January 22, 2020, and which will vest and be settled in common stock on January 22, 2021. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 18:37 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 15,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000497 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,196 F1 · shares: These restricted stock units will vest in full on the earlier of (i) a change of control of Recro Pharma, Inc. (the "Company") (as defined in the Company's 2018 Amended and Restated Equity Incentive Plan) or (ii) December 5, 2020, subject to continued service with the Company. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 18:17 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000474 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,382 F1 · shares: These restricted stock units are scheduled to vest 50% each on December 5, 2020 and December 5, 2021, subject to continued service through the applicable vesting date. F2 · balance_after: Total includes common stock acquired pursuant to a special dividend issued on November 21, 2019, whereby all holders of common stock of Recro Pharma, Inc., as of November 15, 2019, received a dividend of one (1) share of Baudax Bio, Inc. common stock for every two and one-half (2.5) shares of Recro Pharma, Inc. common stock. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 16:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 20,000 | $1.27 | $25,400.00 |
DisclosureSEC source: 0001104659-19-034790 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,568 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.19 to $1.34, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2019 Filed May 16, 2019 21:15 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 6,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-19-000073 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,841 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the vesting date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2019, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 09, 2019 Filed May 10, 2019 16:28 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 10,888 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001192482-19-000249 · edgar.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,888 Underlying: Common Stock · 10,888 shares Expires 2029-05-09 F2 · derivative.exercise_date: The stock option will vest on May 9, 2020. Read SEC document |
| May 09, 2019 Filed May 10, 2019 16:28 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 7,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000249 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,912 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 9, 2020. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:00 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 25,000 | $1.54 | $38,500.00 |
DisclosureSEC source: 0001104659-19-017469 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,568 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.51 to $1.55, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 25, 2019 Filed Apr 1, 2019 17:02 UTC Amendment | AGILE THERAPEUTICS INC AGRX · Entity 87994 | PurchaseCommon Stock | 25,000 | $1.54 | $38,500.00 |
DisclosureSEC source: 0001104659-19-019002 · a4a.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,568 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.51 to $1.55, inclusive. The reporting person undertakes to provide to Agile Therapeutics, Inc., any security holder of Agile Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 21:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,500 | $30.00 | $165,000.00 |
DisclosureSEC source: 0001127430-19-000040 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,942 F1 · price: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:05 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,500 | $27.50 | $151,250.00 |
DisclosureSEC source: 0001127430-19-000032 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,442 F1 · price: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,500 | $25.00 | $137,500.00 |
DisclosureSEC source: 0001127430-19-000029 · edgar.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,942 F1 · price: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 154,400 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-19-004817 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,400 Underlying: Common Stock · 154,400 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 540,900 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001104659-19-004817 · a4.xml · derivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,900 Underlying: Common Stock · 540,900 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionRestricted Stock Units · Derivative | 35,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-003713 · a4.xml · derivative · entry 2 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,314 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: The restricted stock units were granted on January 24, 2018 and were fully vested and delivered on January 24, 2019. F2 · derivative.expiration_date: The restricted stock units were granted on January 24, 2018 and were fully vested and delivered on January 24, 2019. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 17:30 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Exercise / conversionCommon Stock | 35,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-003713 · a4.xml · nonDerivative · entry 1 ALTOMARI ALFRED · CIK 0001285644 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.